The FDA's 7-Step AI Credibility Framework: What Clinical Research Teams Actually Need to Do

Every clinical research team we talk to is in the same spot right now: they’ve deployed AI tools across their workflows — protocol optimization, patient stratification, signal detection, endpoint analysis — and someone on the regulatory or quality side has finally asked the question that keeps everyone up at night: How do we defend this to the FDA?

In January 2025, the FDA gave us the beginning of an answer. The agency published its first-ever draft guidance specifically addressing AI in drug and biological product development — a document titled Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. At its core sits a seven-step credibility assessment framework that every team using AI in a regulated context needs to understand.

This isn’t an abstract policy paper. It’s the framework FDA staff are already using to evaluate submissions that include AI components. And the volume is growing fast — CDER and CBER have collectively received over 1,060 regulatory submissions with AI components since 2016, and that number is accelerating.

We’re going to walk through each of the seven steps, not as a regulatory summary, but as a practitioner’s operating guide. What does each step actually require? Where do clinical research teams stumble? And what should you be doing now — even before this guidance is finalized?

What This Guidance Covers (and What It Doesn’t)

The guidance applies to AI models used in the nonclinical, clinical, post-marketing, and manufacturing phases of the drug product lifecycle — specifically where the AI model produces information or data to support regulatory decision-making about safety, effectiveness, or quality.

It does not cover AI used in drug discovery (the early-stage computational chemistry and target identification work), nor does it cover AI used for internal operational efficiencies — things like resource allocation, drafting regulatory submissions, or managing internal workflows — as long as those uses don’t directly impact patient safety, drug quality, or the reliability of study results.

This distinction matters. If your team is using an LLM to draft a clinical study report, that’s outside the scope. If you’re using a machine learning model to identify which patients should be enrolled in a trial based on electronic health record data, you’re squarely within it.

The Framework: Seven Steps to Establishing AI Model Credibility

The FDA’s framework centers on a single concept: credibility. In the FDA’s framing, credibility is the trust that an AI model’s output is reliable enough for its intended regulatory use. The seven steps are designed to systematically build, document, and evaluate that trust.

Step 1: Define the Question of Interest

Every AI model in a regulated context exists to answer a specific question. The FDA wants that question defined clearly before anything else happens.

This sounds obvious, but it’s where we see teams go sideways most often. The question of interest isn’t “we’re using AI for patient recruitment” — that’s a description of a capability. The question of interest is something like: Can an AI model trained on historical EHR and claims data accurately identify patients who meet the inclusion/exclusion criteria for Protocol XYZ-001 and who are likely to complete the study?

The specificity matters because everything downstream — risk assessment, validation strategy, documentation — flows from how you’ve framed this question.

Step 2: Define the Context of Use (COU)

The context of use takes the question of interest and adds the operational details: what role does the AI model play in the decision-making process? How much human oversight is involved? What are the specific conditions under which the model will operate?

This is where the FDA introduces a critical distinction: the degree of AI autonomy in the decision chain. A model that flags potential safety signals for a human pharmacovigilance specialist to review is a very different context of use from a model that autonomously classifies adverse event severity without human intervention.

Step 3: Assess the AI Model Risk

This is the step that determines how rigorous everything else needs to be. The FDA proposes a risk matrix that maps two dimensions: Model influence — how much does the AI model’s output drive the final decision? And Decision consequence — what happens if the model is wrong?

The FDA illustrates this with a scenario: a drug candidate is associated with life-threatening side effects, and the sponsor proposes using an AI model to categorize patients by adverse event risk. The model would determine whether patients receive outpatient monitoring or inpatient surveillance. If the model incorrectly classifies a high-risk patient as low-risk, the patient could face a life-threatening situation without proper treatment. That’s a high-influence, high-consequence application.

Compliance Callout: Risk Assessment Documentation

The risk matrix isn’t a one-time exercise. If the model’s context of use changes — if it’s applied to a different patient population, a different drug class, or if the degree of human oversight changes — the risk assessment needs to be revisited. Document your risk rationale thoroughly, including the assumptions behind your influence and consequence ratings.

Step 4: Develop a Credibility Assessment Plan

With the risk level established, the next step is building a plan to demonstrate that the model actually works for its intended use. The plan should address: Data quality and fitness for use, Model development and selection, Performance metrics (including uncertainty quantification), Validation strategy (with truly independent test data), and Bias and fairness assessment across demographic subgroups.

Step 5: Execute the Plan

This is the doing — running the validation studies, computing the performance metrics, documenting the results. Every decision made during execution needs to be captured in real time. This is contemporaneous documentation, the kind that 21 CFR Part 11 and GxP environments already demand.

Compliance Callout: 21 CFR Part 11 Implications

If your AI model generates electronic records that will be submitted to the FDA or that form part of the basis for a regulatory decision, those records are subject to 21 CFR Part 11. This means audit trails for model runs, electronic signatures for approvals, access controls for the model and its training data, and validated systems for storing model outputs.

Step 6: Document the Results and Discuss Deviations

The FDA expects comprehensive documentation including results of all planned analyses, any deviations from the original plan, and the rationale for those deviations. Deviations aren’t automatic red flags — what matters is transparency. The documentation package should be structured so that an FDA reviewer can independently evaluate the model’s credibility without needing to rerun any analyses.

Step 7: Determine the Adequacy of the AI Model

The final step is the decision: based on everything documented in Steps 1–6, is this model adequate for its intended context of use? Adequacy isn’t a binary pass/fail. It’s a judgment that considers the model’s demonstrated performance relative to the risk level and whether the residual uncertainties are acceptable given the decision consequences.

This step is also where lifecycle management enters the picture. An adequate model today may become inadequate if the data it processes shifts, if the model’s performance degrades over time, or if the COU changes. The FDA expects sponsors to have a plan for monitoring ongoing adequacy.

Putting It Into Practice: Tools Across the Framework

Understanding the framework in the abstract is one thing. Knowing which tools in your stack actually touch it is what separates preparation from scrambling. Here’s how common AI tools in clinical research map to the credibility assessment.

Evidence Synthesis (Steps 1 & 4): Elicit uses language models to search, filter, and synthesize academic literature — for clinical research teams building a credibility assessment, it’s a significant force multiplier for establishing performance benchmarks and building the evidence base for your credibility plan.

Clinical Data Management (Steps 2 & 5): Workflow automation platforms like Make.com play a supporting role as connective tissue that routes data quality alerts to the right reviewer, timestamps decisions, and creates the audit trail that Steps 5 and 6 demand. Our AI Stack for Clinical Data Management details the full tool landscape.

Safety Monitoring & Pharmacovigilance (Steps 3–6): NLP models for adverse event extraction, ML classifiers for safety report triage, and signal detection algorithms are all squarely within the guidance’s scope. Our AI Stack for Safety Monitoring maps this landscape in detail.

Documentation & Meetings (Steps 5–7): Fireflies.ai addresses a key compliance gap: documenting cross-functional discussions. When your teams meet to review credibility assessment results, those discussions become part of the regulatory record. Fireflies captures meeting transcripts automatically with searchable, timestamped records.

Medical Imaging (Full Framework): If your trial uses an AI model to measure tumor response on imaging, that model needs the full credibility assessment. Our AI Stack for Medical Imaging covers DICOM de-identification, pipeline architecture, and the dual regulatory burden of SaMD and drug development frameworks.

The Regulatory Landscape Is Converging

In January 2026, the FDA and EMA jointly published ten guiding principles for good AI practice across the medicines lifecycle — a significant step toward global regulatory alignment. The EMA finalized its reflection paper on AI in the medicinal product lifecycle in September 2024, and in March 2025 issued its first qualification opinion on an AI methodology.

On the validation side, ISPE published the GAMP Guide: Artificial Intelligence in July 2025 — a 290-page framework for AI-enabled computerized systems in GxP environments. And the European Commission has proposed a new GMP Annex 22 specifically addressing AI in manufacturing.

For clinical research teams, the takeaway is clear: these frameworks are converging on a common set of expectations. Getting ahead of any one of them positions you well for all of them.

The Executive Order Factor

On January 23, 2025 — just 17 days after the FDA published this draft guidance — President Trump signed Executive Order 14148, which rescinded the Biden administration’s EO 14110 on AI safety and directed a review of AI-related policies.

Our recommendation: proceed as if this framework will be finalized. The 7-step framework reflects how FDA staff were already evaluating submissions. Teams that build these practices now will be ahead of the curve no matter what the final guidance says.

What You Should Be Doing Right Now

Inventory your AI models. Catalog every AI tool in use across your organization. For each one, document the question of interest, the context of use, and a preliminary risk assessment.

Start documenting now. Every model you’re currently using without adequate documentation is technical debt. Start capturing training data provenance, model architecture decisions, performance benchmarks, and known limitations for your highest-risk models.

Engage your quality teams early. The credibility assessment framework requires data science and quality teams to work together from Step 1. Start building those cross-functional relationships now.

Map your vendor exposure. If you’re using third-party AI tools in regulated workflows, you inherit the credibility burden. We’ll cover AI vendor qualification in depth later in this series.

Consider early FDA engagement. The FDA encourages sponsors to engage through the CDER AI/ML consultation program. Wait times can extend to several months, so start early.

Compliance Callout: The CDER AI/ML Consultation Program

Sponsors can raise AI credibility questions through pre-IND meetings, Type B pre-submission meetings, or the FDA’s ISTAND pilot program. Document your FDA interactions thoroughly — these exchanges become part of the regulatory record.

The Bottom Line

The FDA’s 7-step framework isn’t a disruption — it’s a formalization. The clinical research organizations that treat AI compliance as a strategic advantage rather than a regulatory burden will be the ones that can deploy AI tools faster, with more confidence, and with less risk of late-stage regulatory pushback.

In the next article in this series, we’ll examine the EMA’s reflection paper and how European regulatory expectations compare to the FDA’s framework.

This article is part of our AI Compliance series. Subscribe to our newsletter to get each new article when it publishes.

Disclaimer: This article is for educational and informational purposes only. It does not constitute legal or regulatory advice. The FDA guidance discussed remains in draft form as of April 2026.